SCHEMBL15437656

SCHEMBL15437656

Cc1noc(-c2ccc(NS(C)(=O)=O)cc2F)c1N(C(=O)O)C(C)c1ccccc1Cl

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 8/20 0.37
SCN5A Q14524 1/20 0.37
DPP4 P27487 2/20 0.35
DPP7 Q9UHL4 2/20 0.35
RORC P51449 2/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
HAVCR2 Q8TDQ0 1/20 0.34
LPAR1 Q92633 1/20 0.34
LPAR2 Q9HBW0 1/20 0.34
LPAR3 Q9UBY5 1/20 0.34
FABP4 P15090 1/20 0.33
FABP5 Q01469 1/20 0.33
MAPT P10636 1/20 0.33
CYP17A1 P05093 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15437515 1.00 SCN9A (0.37) SCN9ASCN5ADPP4DPP7RORC
SCHEMBL15437811 0.92 DPP4 (0.38) SCN9ASCN5ADPP4DPP7RORC
SCHEMBL4037529 0.87 CTSA (0.37) SCN9ADPP4MEN1KMT2ALPAR1
SCHEMBL15437826 0.86 LPAR1 (0.42) RORCLPAR1LPAR2LPAR3MAPT
SCHEMBL15437499 0.86 LPAR1 (0.42) RORCLPAR1LPAR2LPAR3MAPT
SCHEMBL15437305 0.85 LPAR1 (0.38) SCN9ASCN5AMEN1KMT2ALPAR1
SCHEMBL4032080 0.84 MEN1 (0.40) MEN1KMT2ALPAR1LPAR2LPAR3
SCHEMBL15437804 0.83 LPAR1 (0.37) SCN9ASCN5ALPAR1LPAR2LPAR3
SCHEMBL15437474 0.81 SCN9A (0.39) SCN9ASCN5ARORCLPAR1LPAR2
SCHEMBL15437876 0.81 SCN9A (0.39) SCN9ASCN5ARORCLPAR1LPAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785442-B2 Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof CUREGENIX, INC. (CN) 2014-07-22 US claimed
US-20140031353-A1 COMPOUND AS ANTAGONIST OF LYSOPHOSPHATIDIC ACID RECEPTOR, COMPOSITION, AND USE THEREOF CUREGENIX, INC. (CN) 2014-01-30 US claimed
US-8785442-B2 Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof CUREGENIX, INC. (CN) 2014-07-22 US disclosed
US-20140031353-A1 COMPOUND AS ANTAGONIST OF LYSOPHOSPHATIDIC ACID RECEPTOR, COMPOSITION, AND USE THEREOF CUREGENIX, INC. (CN) 2014-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031353-A1 COMPOUND AS ANTAGONIST OF LYSOPHOSPHATIDIC ACID RECEPTOR, COMPOSITION, AND USE THEREOF LPAR1, LPAR2, LPAR5 SCN9A 2398/4885SCN5A 2050/4885DPP4 1375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.